Metastatic Breast Cancer
Conditions
Brief summary
This feasibility study will be conducted in order to provide proof of concept for the CanADVICE+® system comprising a smart phone app and a healthcare organization server side application based on Web 2 technologies. The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
Interventions
DEVICECanADVICE+® (smart phone app)
The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
Sponsors
Royal Marsden NHS Foundation Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with metastatic breast cancer * Commencing first cycle of Capecitabine * Familiar with and own an android smartphone * Willing to participate
Exclusion criteria
* Patients \<18 years * Patients taking part in any other trial containing Capecitabine * Chemotherapy-naïve patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient acceptability of the app using questionnaire provided when patients attend for their 3rd cycle and quantified using a 5-point Likert scale | 42 days | The app will be used at cycles 1 and 2 of capecitabine (each cycle is 21 days), and acceptability of the app will be measured using a questionnaire when patients attend hospital for their 3rd cycle of capecitabine. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Health care provider's acceptability of the app using questionnaires | 48 months | At the end of the study, health care professionals (HCPs) involved in the study will be interviewed using semi-structured interview. |
| Patients' interactivity with the app will be measured using mobile app and web server functions | 42 days | The app will be used at cycles 1 and 2 of capecitabine (each cycle is 21 days). During this period the number of patient interactions with the mobile app and health care professionals interactions with the web server functions will be recorded. |
Countries
United Kingdom
Outcome results
None listed